Mira Pharmaceuticals to Acquire Private Company
Ticker: MIRA · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, pipeline-expansion
TL;DR
Mira Pharma buying a private company to boost its pipeline, deal expected Q4 2024.
AI Summary
Mira Pharmaceuticals, Inc. announced on October 25, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of a private company. The acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This move is part of Mira Pharmaceuticals' strategy to expand its product pipeline.
Why It Matters
This acquisition signals Mira Pharmaceuticals' strategic intent to grow its business and diversify its offerings, potentially impacting its market position and future revenue streams.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies, which could negatively impact Mira Pharmaceuticals.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- October 25, 2024 (date) — Date of Report
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
- 33131 (postal_code) — Principal Executive Offices ZIP
- Mira1a Therapeutics, Inc. (company) — Former Company Name
- 20220112 (date) — Date of Name Change
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K filing is to report on other events, specifically Mira Pharmaceuticals, Inc. entering into a definitive agreement to acquire a private company.
When is the expected closing date for the acquisition?
The acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
What is Mira Pharmaceuticals, Inc.'s strategy behind this acquisition?
The acquisition is part of Mira Pharmaceuticals' strategy to expand its product pipeline.
What was Mira Pharmaceuticals, Inc.'s former name?
Mira Pharmaceuticals, Inc.'s former name was Mira1a Therapeutics, Inc.
Where are Mira Pharmaceuticals, Inc.'s principal executive offices located?
Mira Pharmaceuticals, Inc.'s principal executive offices are located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 14.7 · Accepted 2024-10-25 16:01:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-042511.txt ( ) — 212KB
- mira-20241025.xsd (EX-101.SCH) — 3KB
- mira-20241025_lab.xml (EX-101.LAB) — 33KB
- mira-20241025_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: October 25, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer